Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 155

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Brown, Anna L., Arts, Peer, Carmichael, Catherine L., Babic, Milena, Dobbins, Julia, Chong, Chan-Eng, Schreiber, Andreas W., Feng, Jinghua, Phillips, Kerry, Wang, Paul P. S., Ha, Thuong, Homan, Claire C., King-Smith, Sarah L., Rawlings, Lesley, Vakulin, Cassandra, Dubowsky, Andrew, Burdett, Jessica, Moore, Sarah, McKavanagh, Grace, Henry, Denae, Wells, Amanda, Mercorella, Belinda, Nicola, Mario, Suttle, Jeffrey, Wilkins, Ella, Li, Xiao-Chun, Michaud, Joelle, Brautigan, Peter, Cannon, Ping, Altree, Meryl, Jaensch, Louise, Fine, Miriam, Butcher, Carolyn, D’Andrea, Richard J., Lewis, Ian D., Hiwase, Devendra K., Papaemmanuil, Elli, Horwitz, Marshall S., Natsoulis, Georges, Rienhoff, Hugh Y., Patton, Nigel, Mapp, Sally, Susman, Rachel, Morgan, Susan, Cooney, Julian, Currie, Mark, Popat, Uday, Bochtler, Tilmann, Izraeli, Shai, Bradstock, Kenneth, Godley, Lucy A., Krämer, Alwin, Fröhling, Stefan, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Poplawski, Nicola K., Hahn, Christopher N., Scott, Hamish S.·2020·Blood Advances
DOI 10.1182/bloodadvances.2019000901
Open this paper in CoChat — free account

Abstract

First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000901

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1
Figure 1 CC-BY-NC-ND · From the PDF
Figure 2 Schematic representation of RUNX1 showing the known germline genetic alterations associated with FPD-MM spectrum phenotypes. Shown are all mutations reported in this study, combined with published RUNX1 single-nucleotide variants (SNVs), small insertions and deletions (Indels), and CNVs annotated to RUNX1C; NM_001754.4; LRG_482. Full-mutation annotations can be found in supplemental Table 1. The numbers of the coding exons and known functional domains are shown within the protein, and the number of amino acids are shown below the diagram. The frequency of recurrent mutations is indicated by (N). For all mutations, the protein changes (p.) are shown, unless specified as splice-site variants (SA or SD). SA, splice acceptor; SD, splice donor.
Figure 2 Schematic representation of RUNX1 showing the known germline genetic alterations associated with FPD-MM spectrum phenotypes. Shown are all mutations reported in this study, combined with published RUNX1 single-nucleotide variants (SNVs), small insertions and deletions (Indels), and CNVs annotated to RUNX1C; NM_001754.4; LRG_482. Full-mutation annotations can be found in supplemental Table 1. The numbers of the coding exons and known functional domains are shown within the protein, and the number of amino acids are shown below the diagram. The frequency of recurrent mutations is indicated by (N). For all mutations, the protein changes (p.) are shown, unless specified as splice-site variants (SA or SD). SA, splice acceptor; SD, splice donor.CC-BY-NC-ND · From the PDF
Figure 3 Somatic mutation differences in inherited (germline) and sporadic (somatic) RUNX1 mutated AML. Aggregation of somatic mutations in germline RUNX1 carriers who developed AML as identified through literature review (right). Comparison of the frequency of somatic mutation in myeloid genes in individuals with inherited or sporadic AML (left). *Somatic mutations identified in samples from this study.
Figure 3 Somatic mutation differences in inherited (germline) and sporadic (somatic) RUNX1 mutated AML. Aggregation of somatic mutations in germline RUNX1 carriers who developed AML as identified through literature review (right). Comparison of the frequency of somatic mutation in myeloid genes in individuals with inherited or sporadic AML (left). *Somatic mutations identified in samples from this study.CC-BY-NC-ND · From the PDF
Figure 4 The spectrum of hematological phenotypes reported with different germline RUNX1 mutations. The protein (p.) changes are shown, for frameshift (fs), stop-gain (*), and missense variants. Splice-site variants are shown with the cDNA change (c.), and (partial) gene deletions are abbreviated. CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CMMoL, chronic myelomonocytic leukemia; Del, deletion; DLBCL, diffuse large B-cell lymphoma; Dup, duplication; Ex, Exon; HCL, hairy cell leukemia; MF, myelofibrosis; SCC, squamous cell carcinoma.
Figure 4 The spectrum of hematological phenotypes reported with different germline RUNX1 mutations. The protein (p.) changes are shown, for frameshift (fs), stop-gain (*), and missense variants. Splice-site variants are shown with the cDNA change (c.), and (partial) gene deletions are abbreviated. CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CMMoL, chronic myelomonocytic leukemia; Del, deletion; DLBCL, diffuse large B-cell lymphoma; Dup, duplication; Ex, Exon; HCL, hairy cell leukemia; MF, myelofibrosis; SCC, squamous cell carcinoma.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 81

  1. Song, 1999, Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia, Nat Genet, 23, 166, 10.1038/13793 · DOI · Paper page
  2. Brown, 2017, Recognition of familial myeloid neoplasia in adults, Semin Hematol, 54, 60, 10.1053/j.seminhematol.2016.11.003 · DOI
  3. Sood, 2017, Role of RUNX1 in hematological malignancies, Blood, 129, 2070, 10.1182/blood-2016-10-687830 · DOI
  4. Antony-Debré, 2016, Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia, Leukemia, 30, 999, 10.1038/leu.2015.236 · DOI
  5. Churpek, 2015, Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia, Blood, 126, 2484, 10.1182/blood-2015-04-641100 · DOI · Paper page
  6. Yoshimi, 2014, Recurrent CDC25C mutations drive malignant transformation in FPD/AML, Nat Commun, 5, 4770, 10.1038/ncomms5770 · DOI
  7. Kanagal-Shamanna, 2017, Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation, Haematologica, 102, 1661, 10.3324/haematol.2017.167726 · DOI
  8. Stengel, 2018, Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML, Leukemia, 32, 295, 10.1038/leu.2017.239 · DOI
  9. Gaidzik, 2016, RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features [published correction appears in Leukemia. 2016;30(11):2282, Leukemia, 30, 2160, 10.1038/leu.2016.126 · DOI
  10. Luo, 2019, ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants, Blood Adv, 3, 2962, 10.1182/bloodadvances.2019000644 · DOI
  11. Hahn, 2015, A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone, Leukemia, 29, 2101, 10.1038/leu.2015.67 · DOI
  12. Favero, 2015, Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data, Ann Oncol, 26, 64, 10.1093/annonc/mdu479 · DOI
  13. Singhal, 2019, The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution, Leukemia, 33, 2842, 10.1038/s41375-019-0479-8 · DOI · Paper page
  14. Tahirov, 2001, Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta, Cell, 104, 755, 10.1016/S0092-8674(01)00271-9 · DOI
  15. Johnson, 2016, Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects, Haematologica, 101, 1170, 10.3324/haematol.2016.146316 · DOI
  16. Preudhomme, 2009, High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder, Blood, 113, 5583, 10.1182/blood-2008-07-168260 · DOI
  17. Osato, 1999, Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias, Blood, 93, 1817, 10.1182/blood.V93.6.1817.406k36_1817_1824 · DOI
  18. Owen, 2008, Familial myelodysplasia and acute myeloid leukaemia–a review, Br J Haematol, 140, 123, 10.1111/j.1365-2141.2007.06909.x · DOI
  19. Owen, 2008, Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy, Blood, 112, 4639, 10.1182/blood-2008-05-156745 · DOI · Paper page
  20. Pastor, 2017, Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants, Leukemia, 31, 759, 10.1038/leu.2016.342 · DOI
  21. Stockley, 2013, Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects, Blood, 122, 4090, 10.1182/blood-2013-06-506873 · DOI
  22. Latger-Cannard, 2016, Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders, Orphanet J Rare Dis, 11, 49, 10.1186/s13023-016-0432-0 · DOI
  23. Michaud, 2002, In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis, Blood, 99, 1364, 10.1182/blood.V99.4.1364 · DOI
  24. Simon, 2017, Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity, Clin Cancer Res, 23, 6969, 10.1158/1078-0432.CCR-17-1259 · DOI
  25. De Rocco, 2017, Mutations of RUNX1 in families with inherited thrombocytopenia, Am J Hematol, 92, E86, 10.1002/ajh.24703 · DOI
  26. Perez Botero, 2017, Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia, Leuk Lymphoma, 58, 1963, 10.1080/10428194.2016.1265118 · DOI
  27. Sun, 2004, Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation, Blood, 103, 948, 10.1182/blood-2003-07-2299 · DOI · Paper page
  28. Ouchi-Uchiyama, 2015, Analyses of Genetic and Clinical Parameters for Screening Patients With Inherited Thrombocytopenia with Small or Normal-Sized Platelets, Pediatr Blood Cancer, 62, 2082, 10.1002/pbc.25668 · DOI
  29. Guidugli, 2017, Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes, Leukemia, 31, 1226, 10.1038/leu.2017.28 · DOI
  30. Walker, 2002, A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia, Br J Haematol, 117, 878, 10.1046/j.1365-2141.2002.03512.x · DOI
  31. Schwartz, 2017, The genomic landscape of pediatric myelodysplastic syndromes, Nat Commun, 8, 1557, 10.1038/s41467-017-01590-5 · DOI
  32. Béri-Dexheimer, 2008, Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions, Eur J Hum Genet, 16, 1014, 10.1038/ejhg.2008.89 · DOI
  33. Marneth, 2017, Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders, Blood, 129, 1733, 10.1182/blood-2016-11-749366 · DOI
  34. DiNardo, 2016, Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC), Clin Lymphoma Myeloma Leuk, 16, 417, 10.1016/j.clml.2016.04.001 · DOI
  35. Bluteau, 2011, Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia, Blood, 118, 6310, 10.1182/blood-2010-12-325555 · DOI
  36. Haslam, 2016, Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia, Br J Haematol, 175, 161, 10.1111/bjh.13838 · DOI
  37. Obata, 2015, Whole-exome sequencing confirmation of a novel heterozygous mutation in RUNX1 in a pregnant woman with platelet disorder, Platelets, 26, 364, 10.3109/09537104.2014.912750 · DOI
  38. Sakurai, 2016, Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele, Blood Cancer J, 6, e392, 10.1038/bcj.2015.81 · DOI
  39. Chin, 2016, RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity, Blood Cancer J, 6, e379, 10.1038/bcj.2015.105 · DOI
  40. Buijs, 2012, Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees, Leukemia, 26, 2151, 10.1038/leu.2012.79 · DOI
  41. Ng, 2018, Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation, Biomark Res, 6, 16, 10.1186/s40364-018-0130-2 · DOI
  42. Zhang, 2015, Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity, Haematologica, 100, 42, 10.3324/haematol.2014.113456 · DOI
  43. Chisholm, 2019, Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy, Pediatr Dev Pathol, 22, 315, 10.1177/1093526618822108 · DOI
  44. Badin, 2017, Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation, Haemophilia, 23, e204, 10.1111/hae.13169 · DOI
  45. Manchev, 2017, Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0, J Cell Mol Med, 21, 1237, 10.1111/jcmm.13051 · DOI
  46. Langabeer, 2010, A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals, Eur J Haematol, 85, 552, 10.1111/j.1600-0609.2010.01513.x · DOI
  47. Buijs, 2001, A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies, Blood, 98, 2856, 10.1182/blood.V98.9.2856 · DOI
  48. Ripperger, 2009, A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation?, Leukemia, 23, 1364, 10.1038/leu.2009.87 · DOI
  49. Nishimoto, 2010, T cell acute lymphoblastic leukemia arising from familial platelet disorder, Int J Hematol, 92, 194, 10.1007/s12185-010-0612-y · DOI
  50. Tawana, 2017, Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree, Eur J Hum Genet, 25, 1020, 10.1038/ejhg.2017.80 · DOI
  51. Holme, 2012, Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia, Br J Haematol, 158, 242, 10.1111/j.1365-2141.2012.09136.x · DOI
  52. Linden, 2010, Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation, Br J Haematol, 151, 528, 10.1111/j.1365-2141.2010.08370.x · DOI
  53. Heller, 2005, Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation, Blood, 105, 4664, 10.1182/blood-2005-01-0050 · DOI · Paper page
  54. Appelmann, 2009, Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene, Ann Hematol, 88, 1037, 10.1007/s00277-009-0722-x · DOI
  55. Schmit, 2015, Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome, Leuk Res Rep, 4, 24
  56. Ok, 2016, Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy, Am J Clin Pathol, 145, 271, 10.1093/ajcp/aqv080 · DOI
  57. Shiba, 2012, CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML), Blood, 119, 2612, 10.1182/blood-2011-02-333435 · DOI
  58. Staňo Kozubík, 2018, C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies, Int J Hematol, 108, 652, 10.1007/s12185-018-2514-3 · DOI
  59. Churpek, 2010, Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder, Leuk Lymphoma, 51, 1931, 10.3109/10428194.2010.503821 · DOI
  60. Yoshimi, 2016, Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan, Ann Oncol, 27, 887, 10.1093/annonc/mdw066 · DOI
  61. Sorrell, 2012, Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype, Int J Clin Med, 3, 37110, 10.4236/ijcm.2012.37110 · DOI
  62. Cavalcante de Andrade Silva, 2018, Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia, Cancer Genet, 222-223, 32, 10.1016/j.cancergen.2018.01.002 · DOI
  63. Jongmans, 2010, Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome, Leukemia, 24, 242, 10.1038/leu.2009.210 · DOI
  64. Shinawi, 2008, Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q, Blood, 112, 1042, 10.1182/blood-2008-01-135970 · DOI
  65. van der Crabben, 2010, Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation, Leuk Res, 34, e8, 10.1016/j.leukres.2009.06.030 · DOI
  66. Hoyer, 2007, Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays, J Med Genet, 44, 629, 10.1136/jmg.2007.050914 · DOI
  67. Lyle, 2009, Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21, Eur J Hum Genet, 17, 454, 10.1038/ejhg.2008.214 · DOI · Paper page
  68. Katzaki, 2010, Syndromic mental retardation with thrombocytopenia due to 21q22.11q22.12 deletion: Report of three patients, Am J Med Genet A, 152A, 1711, 10.1002/ajmg.a.33478 · DOI
  69. Link, 2016, “CHIP”ping away at clonal hematopoiesis, Leukemia, 30, 1633, 10.1038/leu.2016.130 · DOI
  70. Valent, 2019, Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML, Int J Mol Sci, 20, 789, 10.3390/ijms20030789 · DOI
  71. Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci USA, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  72. Hong, 2019, RUNX1-dependent mechanisms in biological control and dysregulation in cancer, J Cell Physiol, 234, 8597, 10.1002/jcp.27841 · DOI
  73. Patrick, 2019, Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC, Front Genet, 10, 304, 10.3389/fgene.2019.00304 · DOI
  74. Helms, 2003, A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis, Nat Genet, 35, 349, 10.1038/ng1268 · DOI
  75. Yin, 2015, Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility, Nat Commun, 6, 6916, 10.1038/ncomms7916 · DOI
  76. Tokuhiro, 2003, An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis, Nat Genet, 35, 341, 10.1038/ng1267 · DOI
  77. Chiaroni-Clarke, 2014, Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis, Pediatr Rheumatol Online J, 12, 53, 10.1186/1546-0096-12-53 · DOI
  78. Jones, 2009, JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms, Nat Genet, 41, 446, 10.1038/ng.334 · DOI
  79. Thol, 2017, Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis, Leukemia, 31, 1286, 10.1038/leu.2016.345 · DOI
  80. Adelman, 2019, Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia, Cancer Discov, 9, 1080, 10.1158/2159-8290.CD-18-1474 · DOI
  81. Hamilton, 2019, Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?, J Clin Oncol, 37, 2098, 10.1200/JCO.19.00181 · DOI

Cited by

See all 155

Metadata

Authors
Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C.-E., Schreiber, A. W., Feng, J., Phillips, K., Wang, P. P. S., Ha, T., Homan, C. C., King-Smith, S. L., Rawlings, L., Vakulin, C., Dubowsky, A., Burdett, J., Moore, S., McKavanagh, G., Henry, D., Wells, A., Mercorella, B., Nicola, M., Suttle, J., Wilkins, E., Li, X.-C., Michaud, J., Brautigan, P., Cannon, P., Altree, M., Jaensch, L., Fine, M., Butcher, C., D’Andrea, R. J., Lewis, I. D., Hiwase, D. K., Papaemmanuil, E., Horwitz, M. S., Natsoulis, G., Rienhoff, H. Y., Patton, N., Mapp, S., Susman, R., Morgan, S., Cooney, J., Currie, M., Popat, U., Bochtler, T., Izraeli, S., Bradstock, K., Godley, L. A., Krämer, A., Fröhling, S., Wei, A. H., Forsyth, C., Mar Fan, H., Poplawski, N. K., Hahn, C. N., & Scott, H. S.
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2020-03-24
Volume
4
Issue
6
Pages
1131-1144
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2019000901
Cited by
155
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review